Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cardiovascular Disorders
Published in: BMC Cardiovascular Disorders 1/2017

Open Access 01-12-2017 | Research article

Plasma homocysteine levels associated with a corrected QT interval

Authors: Zhao Li, Xiaofan Guo, Guozhe Sun, Liqiang Zheng, Yingxian Sun, Yamin Liu, Maria Roselle Abraham

Published in: BMC Cardiovascular Disorders | Issue 1/2017

Login to get access

Abstract

Background

Little is known about the relationship between homocysteine (Hcy) levels and the QT interval. We examined the association of different Hcy levels with corrected QT (QTc) intervals in a general population.

Methods

Plasma levels of Hcy were assessed in a population-based study of 7002 participants 35 years of age and older from 2012 to 2013. Twelve-lead ECGs were performed on all participants and analyzed automatically.

Results

The distribution of Hcy levels was determined for an entire population after the data were grouped into quartiles (Q1: <=11.1umol/L; Q2: 11.1–13.8umol/L; Q3: 13.8–18.2 umol/L; Q4 > 18.2 umol/L). The mean value of the QTc interval in each quartile was 433.2 ± 23.8 ms, 430.0 ± 24.6 ms, 429.2 ± 24.5 ms and 430.6 ± 25.7 ms. Multiple logistic regression analyses showed that, compared with the second quartile, and after fully adjusting for potential confounding factors, the odds for QTc > 440 ms in the first and fourth quartile increased (P < 0.05), (OR: 1.23, 95% CI: 1.05–1.43 for Q1; OR: 1.40, 95% CI: 1.19–1.65 for Q4).

Conclusions

QTc interval was associated with the Hcy level in this general population.
Appendix
Available only for authorised users
Literature
1.
Nygård O, Vollset SE, Refsum H, Stensvold I, et al. Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study JAMA. 1995;274(19):1526–33.PubMed
2.
Xanthakis V, Enserro DM, Murabito JM, et al. Ideal cardiovascular health: associations with biomarkers and subclinical disease and impact on incidence of cardiovascular disease in the Framingham offspring study. Circulation. 2014;130(19):1676–83.CrossRefPubMed
3.
4.
Nasir K, Tsai M, Rosen BD, et al. Elevated homocysteine is associated with reduced regional left ventricular function: the Multi-Ethnic Study of Atherosclerosis. Circ. 2007;115(2):180–7.CrossRef
5.
Verdoia M, Schaffer A, Pergolini P, et al. Homocysteine Levels Influence Platelet Reactivity in Coronary Artery Disease Patients Treated With Acetylsalicylic Acid. J Cardiovasc Pharmacol. 2015;66(1):35–40.CrossRefPubMed
6.
Pakfetrat M, Shahroodi JR, Zolgadr AA, et al. Effects of zinc supplement on plasma homocysteine level in end-stage renal disease patients: a double-blind randomized clinical trial. Biol Trace Elem Res. 2013;153(1–3):11–5.CrossRefPubMed
7.
Fu Z, Qian G, Xue H, et al. Hyperhomocysteinemia is an independent predictor of long-term clinical outcomes in Chinese octogenarians with acute coronary syndrome. Clin Interv Aging. 2015;10:1467–74.CrossRefPubMedPubMedCentral
8.
Shontz RD, Xu Z, Patel KP, et al. Inhibition of K+ currents by homocysteine in rat ventricular myocytes. J Cardiovasc Electrophysiol. 2001;12(2):175–82.CrossRefPubMed
9.
Pacher P, Ungvari Z, Kecskemeti V. Electrophysiological effects of homocysteine in isolated rat right ventricular papillary muscles and left atria. Gen Pharmacol. 1999;32:439–43.CrossRefPubMed
10.
Wenzel Seifert K, Wittmann M, Haen E. QTc prolongation by psychotropic drugs and the risk of torsade de pointes. Dtsch Arztebl Int. 2011;108(41):687–93.PubMedPubMedCentral
11.
Rosenberger D, Gargoum R, Tyagi N, et al. Homocysteine enriched diet leads to prolonged QT interval and reduced left ventricular performance in telemetric monitored mice. Nutr Metab Cardiovasc Dis. 2011;21(7):492–8.CrossRefPubMed
12.
Upadhya B, Ntim W, Brandon Stacey R, et al. Prolongation of QTc interval and risk of death among patients with sickle cell disease. Eur J Haematol. 2013;91(2):170–8.CrossRefPubMed
13.
Acampa M, Lazzerini PE, Guideri F, et al. Homocysteine and P wave dispersion in patients with heart transplantation. Clin Transpl. 2011;25(1):119–25.CrossRef
14.
Munjal C, Tyagi N, Lominadze D, et al. Matrix metalloproteinase-9 in homocysteine-induced intestinal microvascular endothelial paracellular and transcellular permeability. J Cell Biochem. 2012;113(4):1159–69.CrossRefPubMedPubMedCentral
15.
Moshal KS, Metreveli N, Frank I, et al. Mitochondrial MMP activation, dysfunction and arrhythmogenesis in hyperhomocysteinemia. Curr Vasc Pharmacol 2008; 6(2):84–92. Review. .
16.
Panoulas VF, Toms TE, Douglas KM, et al. Prolonged QTc interval predicts all-cause mortality in patients with rheumatoid arthritis: an association driven by high inflammatory burden. Rheumatology (Oxford). 2014;53(1):131–7.CrossRef
17.
Nielsen JB, Graff C, Rasmussen PV, et al. Risk prediction of cardiovascular death based on the QTc interval: evaluating age and gender differences in a large primary care population. Eur Heart J. 2014;35(20):1335–44.CrossRefPubMedPubMedCentral
18.
Selker HP, Raitt MH, Schmid CH, et al. Time-dependent predictors of primary cardiac arrest in patients with acute myocardial infarction. Am J Cardiol. 2003;91(3):280–6.CrossRefPubMed
19.
Lai CC, Hsiao HC, Hsiao SH, et al. Role of shortened QTc dispersion in in-hospital cardiac events in patients undergoing percutaneous coronary intervention for acute coronary syndrome. J Chin Med Assoc. 2006;69(7):297–303.CrossRefPubMed
20.
Li Z, Guo X, Chen S, et al. Hyperhomocysteinemia independently associated with the risk of hypertension: a cross-sectional study from rural China. J Hum Hypertens. 2015; 9:1–5.
21.
Sun GZ, Guo L, Wang XZ, Song HJ, Li Z, Wang J, Sun YX. Prevalence of atrial fibrillation and its risk factors in rural China: a cross-sectional study. Int J Cardiol. 2015;26:13–7.CrossRef
22.
Guo X, Li Z, Sun G, et al. Comparison of four nontraditional lipid profiles in relation to ischemic stroke among hypertensive Chinese population. Int J Cardiol. 2015;201:123–5.CrossRefPubMed
23.
Sun GZ, Guo L, Wang XZ, et al. Prevalence of atrial fibrillation and its risk factors in rural China: a cross-sectional study. Int J Cardiol. 2015;182:13–7.CrossRefPubMed
24.
Panagiotakos DB, Pitsavos C, Chrysohoou C, et al. Epidemiology of overweight and obesity in a Greek adult population: the ATTICA study. Obes Res. 2004;12:1914–20.CrossRefPubMed
25.
O’Brien E, Petrie J, Littler W, et al. The British hypertension society protocol for the evaluation of automated and semi-automated blood pressure measuring devices with special reference to ambulatory systems. J Hypertens. 1990;8:607–19.CrossRefPubMed
26.
Leng YLY, Zhou Y, Ke H, et al. Electrocardiogram derived QRS duration> 120 ms is associated with elevated plasma homocysteine levels in a rural Australian cross-sectional population[J]. Medicine. 2015;94(27):1–5.CrossRef
27.
Bazett HC. An analysis of the time relations of electrocardiograms. Heart. 1920;7:353–67.
28.
Sagie A, Larson MG, Goldberg RJ, et al. An improved method for adjusting the QT interval for heart rate (the Framingham heart study). Am J Cardiol. 1992;70(7):797–801.CrossRefPubMed
29.
Fridericia LS. EKG systolic duration in normal subjects and heart disease patients. Acta Med Scand. 1920;53:469–88.CrossRef
30.
Schwartz PJ, Moss AJ, Vincent GM, et al. Diagnostic criteria for the long QT syndrome. An update Circulation. 1993;88(2):782–4.CrossRefPubMed
31.
Akintunde AA1, Oyedeji AT, Familoni OB, et al. QT Interval prolongation and dispersion: Epidemiology and clinical correlates in subjects with newly diagnosed systemic hypertension in Nigeria. J Cardiovasc Dis Res. 2012;3:290–5.CrossRefPubMedPubMedCentral
32.
Neyroud N, Maison-Blanche P, Denjoy I, et al. Diagnostic performance of QT interval variables from 24-h electrocardiography in the long QT syndrome. Eur Heart J. 1998;19:158–65.CrossRefPubMed
33.
Duyuler S, Türker Duyuler P, Batur MK. Impact of iron and homocysteine levels on T peak-to-end interval and Tp-e/QT ratio in elite athletes. Ann Noninvasive Electrocardiol. 2016; doi:10.​1111/​anec.​12365. [Epub ahead of print]
34.
Naji F, Suran D, Kanic V, et al. High homocysteine levels predict the recurrence of atrial fibrillation after successful electrical cardioversion. Int Heart J. 2010;51(1):30–3.CrossRefPubMed
35.
36.
Marcucci R, Betti I, Cecchi E, et al. Hyperhomocysteinemia and vitamin B6 deficiency: new risk markers for nonvalvular atrial fibrillation? Am Heart J. 2004;148(3):456–61.CrossRefPubMed
37.
Cai BZ, Gong DM, Liu Y, et al. Homocysteine inhibits potassium channels in human atrial myocytes. Clin Exp Pharmacol Physiol 2007;34(9):851–855. PubMed.
38.
Cai B, Gong D, Pan Z, et al. Large-conductance Ca2+−activated K+ currents blocked and impaired by homocysteine in human and rat mesenteric artery smooth muscle cells. Life Sci. 2007;80(22):2060–6.CrossRefPubMed
39.
Hamed SA, Nabeshima T. The high atherosclerotic risk among epileptics: the atheroprotective role of multivitamins. J Pharmacol Sci 2005;98(4):340–353 Review.
40.
Cai B, Shan L, Gong D, et al. Homocysteine modulates sodium channel currents in human atrial myocytes. Toxicology. 2009;256(3):201–6.CrossRefPubMed
41.
Twardowski T, Jakubowski H. Mechanisms of homocysteine toxicity in humans[J]. Amino Acids. 2007;32(4):561–72.CrossRefPubMed
42.
Acampa M, Lazzerini PE, Guideri F, et al. Ischemic stroke after heart transplantation. Journal of stroke. 2016;2:1–12.
Metadata
Title
Plasma homocysteine levels associated with a corrected QT interval
Authors
Zhao Li
Xiaofan Guo
Guozhe Sun
Liqiang Zheng
Yingxian Sun
Yamin Liu
Maria Roselle Abraham
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Cardiovascular Disorders / Issue 1/2017
Electronic ISSN: 1471-2261
DOI
https://doi.org/10.1186/s12872-017-0617-z

Other articles of this Issue 1/2017

BMC Cardiovascular Disorders 1/2017 Go to the issue

Research article

Unloading shoes for intermittent claudication: a randomised crossover trial

Research article

Clinical outcomes of conventional surgery versus MitraClip® therapy for moderate to severe symptomatic mitral valve regurgitation in the elderly population: an institutional experience

Research article

The top tertile of hematocrit change during hospitalization is associated with lower risk of mortality in acute heart failure patients

Research article

Longitudinal shortening remains the principal component of left ventricular pumping in patients with chronic myocardial infarction even when the absolute atrioventricular plane displacement is decreased

Case report

Aeroembolism in left atrium during catheter ablation of atrial fibrillation in a patient with dextrocardia: a case report and review of the literature

Study protocol

Identification of new biosignatures for clinical outcomes in stable coronary artery disease - The study protocol and initial observations of a prospective follow-up study in Taiwan

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits